Searches , social queries for TOCERANIB
Search references for TOCERANIB. Phrases containing TOCERANIB
See searches and references containing TOCERANIB!
Search references for TOCERANIB. Phrases containing TOCERANIB
See searches and references containing TOCERANIB!TOCERANIB
Chemical compound used in the treatment of tumors
Toceranib (INN), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also
Toceranib
Pharmaceutical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Brelgometon
TrkA and TrkB positive modulator
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
ACD856
Pharmaceutical drug classification
L01EX27 Capivasertib L01EX28 Repotrectinib L01EX29 Vimseltinib QL01EX90 Toceranib L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab L01FB01 Inotuzumab
ATC_code_L01
Small tumor composed of mast cells
lomustine are common chemotherapy agents used to treat mast cell tumors. Toceranib and masitinib, examples of receptor tyrosine kinase inhibitors, are used
Mastocytoma
Primary male sex hormone
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Testosterone
Medication
(Avapritinib Axitinib Masitinib Pazopanib Ripretinib Sorafenib Sunitinib Toceranib) FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK)) VEGFR Axitinib Cediranib
Elranatamab
Class of proteins
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Hemopoietic_growth_factor
Corticosteroid medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Dexamethasone
Anti-cancer medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Dabrafenib
Monoclonal antibody
(Avapritinib Axitinib Masitinib Pazopanib Ripretinib Sorafenib Sunitinib Toceranib) FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK)) VEGFR Axitinib Cediranib
Mosunetuzumab
Signaling glycoprotein regulating cell proliferation
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Platelet-derived growth factor
Platelet-derived_growth_factor
Generating of neurons from neural stem cells in adults
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Adult_neurogenesis
Tricyclic antidepressant
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Amitriptyline
Medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Trastuzumab_deruxtecan
Medication for macular degeneration
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Faricimab
American multinational pharmaceutical and biotechnology corporation
for human use by the FDA in January 2006. A related compound, SU11654 (Toceranib), was also approved for cancer in dogs, and the ALK inhibitor Crizotinib
Pfizer
Index of chemical compounds with the same molecular formula
(molar mass: 396.458 g/mol, exact mass: 396.1962 u) may refer to: PX-2 Toceranib This set index page lists chemical structure articles associated with
C22H25FN4O2
Medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Filgrastim
Medication
(Avapritinib Axitinib Masitinib Pazopanib Ripretinib Sorafenib Sunitinib Toceranib) FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK)) VEGFR Axitinib Cediranib
Zilurgisertib
Protein involved in blood vessel growth
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Vascular endothelial growth factor
Vascular_endothelial_growth_factor
Protein found in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Insulin-like_growth_factor_1
Protein-coding gene in the species Homo sapiens
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
FGF19
Cancer tumor in dogs
two tyrosine kinase inhibitors - masitinib (trade name Masivet) and toceranib (trade name Palladia) - have been approved for the treatment of mastocytomas
Mastocytoma_in_dogs
Protein that stimulates red blood cell production
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Erythropoietin
Anticancer medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Trametinib
Pharmaceutical drug
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Cetuximab
Protein found in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
ERBB3
Medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Fruquintinib
(INN) Tobrasone Tobrex tobuterol (INN) tocainide (INN) tocamphyl (INN) toceranib (USAN, INN) tocilizumab (INN) tocilizumab-aazg tocilizumab-anoh tocilizumab-bavi
List_of_drugs:_Tj–Tq
Family of proteins involved in anatomical development
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Fibroblast_growth_factor
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Dehydroepiandrosterone
Protein that stimulates cell division and differentiation
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Epidermal_growth_factor
Experimental drug for neurodegenerative disorders
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Cerebrolysin
Protein found in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Brain-derived neurotrophic factor
Brain-derived_neurotrophic_factor
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Dihexa
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
ANA-12
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Fosgonimeton
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Lenvatinib
Pharmaceutical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Braegen-02
Medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Trastuzumab
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Tropoflavin
Combination drug
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Pertuzumab/trastuzumab/hyaluronidase
Pertuzumab/trastuzumab/hyaluronidase
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Axitinib
Peptide hormone
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Insulin
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Crenolanib
Protein capable of worsening malignant diseases
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Hepatoma-derived growth factor
Hepatoma-derived_growth_factor
Combination cancer medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Avutometinib/defactinib
Combination drug
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Mecasermin_rinfabate
Protein-coding gene in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Betacellulin
Mammalian protein found in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
C-fos-induced_growth_factor
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Cabozantinib
Drug typically used in cancer treatment
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Tyrosine_kinase_inhibitor
Protein-coding gene in the species Homo sapiens
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Angiopoietin_4
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Nintedanib
Class of enzymes
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Receptor_tyrosine_kinase
Drug for the treatment of lung carninoma
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Dacomitinib
Mammalian protein found in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Nerve_growth_factor
Medication which blocks growth of blood vessels
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Anti-VEGF
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Encorafenib
Medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Repotrectinib
Class of drugs used to treat malignant tumors
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Antineoplastic
Protein-coding gene in the species Homo sapiens
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
EPH_receptor_A5
Chemical compound, used as a medication to treat lung cancer
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Osimertinib
Cancer treatment medicine
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Sorafenib
Pharmaceutical drug
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Alacizumab_pegol
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Imatinib
Protein-coding gene in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
EPHA8
Protein-coding gene in the species Homo sapiens
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Fibroblast growth factor receptor 2
Fibroblast_growth_factor_receptor_2
Group of signal transduction pathways involved in embryonic development
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Wnt_signaling_pathway
Pharmaceutical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
E2511
Mammalian protein and protein-coding gene
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
KIT_gene
Pharmaceutical drug
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Ranibizumab
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Avapritinib
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Fulranumab
Monoclonal antibody
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Futuximab
Medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Amivantamab/hyaluronidase
Medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Bevacizumab
Medication and naturally occurring steroid hormone
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Testosterone_(medication)
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Eutropoflavin
Transmembrane protein
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Epidermal growth factor receptor
Epidermal_growth_factor_receptor
Protein hormone
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Insulin-like_growth_factor_2
Protein or other substance that stimulates cellular proliferation
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Growth_factor
Family of proteins
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Neurotrophin
Cancer medication
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Sunitinib
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Afatinib
Synthetic protein
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
IGF-1_LR3
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Dasatinib
Chemical compound
intermediate with oxindole (3) in the presence of base yields semaxanib. Toceranib World Health Organization (2001). "International Nonproprietary Names
Semaxanib
Protein-coding gene in the species Homo sapiens
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Fibroblast growth factor receptor 4
Fibroblast_growth_factor_receptor_4
Drug discovery company
(Sunitinib) was later approved for human use, and a related compound SU11654 (Toceranib) was approved for canine tumors. Sugen was funded through a number of
SUGEN
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
N-Acetylserotonin
Medication for treatment of non-small-cell lung cancer
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Erlotinib
Chemical compound
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Ponazuril
Mammalian protein found in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
HER2
Protein and coding gene in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Tropomyosin_receptor_kinase_B
Monoclonal antibody
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Pegfilgrastim
Protein found in humans
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Fibroblast growth factor receptor-like 1
Fibroblast_growth_factor_receptor-like_1
ALK inhibitor for treatment of non-small-cell lung cancer
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Alectinib
Family of biomolecules
Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) GFRα1 Agonists:
Neurotrophic_factors
travel, tourism, insurance
TOCERANIB
TOCERANIB
TOCERANIB
TOCERANIB
TOCERANIB
TOCERANIB
TOCERANIB
TOCERANIB
TOCERANIB
travel, tourism, insurance